Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients

Hematology

Volumn 19, Issue 3, 2014, Pages 123-128

  Elghannam, Doaa M ^a   Ibrahim, Lamia ^a   Ebrahim, Mohamed A ^a   Azmy, Emad ^a   Hakem, Hazem ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Chronic myeloid leukemia; Imatinib; MDR1 gene; Polymorphism

Indexed keywords

IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ALLELE; ARTICLE; BLOOD CELL COUNT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DRUG RESISTANCE; EGYPT; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

ADULT; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; EGYPT; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; P-GLYCOPROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84897890373     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000102     Document Type: Article

References (31)

1. Hochhaus A. Chronic myelogenous leukemia (CML) resistance to tyrosine kinase inhibitors. Ann Oncol. 2006;17:274-9.
2. Sailaja K, Surekha D, Rao DN, Raghunadharao D, Vishnupriya S. Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia Biology and Medicine. 2010;2 (4):17-21.
3. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-41.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-80.
5. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101: 2368-73.
6. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990;265:506-14.
7. Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, et al. The MDR1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 1986;141:956-62.
8. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
9. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, et al. Imatinib deposition and ABCB1(MDR1, Pglycoprotein) genotype. Clin Pharmacol Ther. 2007;82(1): 33-40.
10. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794(5):860-71.
11. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811): 525-8.
12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-8.
13. Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract. 2010; 16:39-44.
14. Gervasini G, Pharma D, Carrillo JA, Garcia M, Jose CS, Cabanillas A, et al. Binding Cassette B1 (ABCB1) (Multidrug Resistance 1) G2677t/a Gene polymorphism is associated with high risk of lung cancer. Adenosine Triphosphate. Cancer 2006;107(12):2850-6.
15. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the Pglycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002;7: 1847-54.
16. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, et al. MDR1 genotype is associated with hepatic cytochrome P4503A4 basal land induction phenotype. Clin Pharmacol Ther. 2006;79:325-38.
17. Kurata Y, Ieiri I, KimuraM, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Therapeut. 2002;72:209-19.
18. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Therapeut. 2001; 297(3):1137-43.
19. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112(5):2024-7.
20. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S; European Leukemia Net. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 2009;22(3):331-41.
21. Druker BJ, Lee SJ. Chronic leukemias. In: Devita VT, Hellman S, Rosenberg SA (eds.) Cancer, principles and practice of oncology. 7th ed. Philadelphia: Pubmed Lippincott; 2005. p. 2124.
22. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetics Nomenclature. 3rd ed. Basel, Switzerland: Karger Publishing; 2009, pp 364-372.
23. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67:9609-12.
24. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics. 2007; 8(1):29-39.
25. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, et al. P glycoprotein gene (MDR1) cDNA from human adrenal. normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun. 1989;162:224-31.
26. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189-99.
27. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28:265-9.
28. Kim DH, Sriharsha L, XuW, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009; 15:4750-8.
29. Van Den MM, Heuvel-Eibrink EA, Weimer MJ, De Boevere B, Van Der Holt PJ, Vossebeld R, et al. MDR1 gene related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97: 3605-11.
30. Goreva OB, Grishanova AY, Domnikova NP, Mukhin OV, Lyakhovich VV. MDR1 gene C1236T and C6+139T polymorphisms in the Russian population: associations with predisposition to lymphoproliferative diseases and drug resistance. Bull Exp Biol Med. 2004;138:404-6.
31. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12:437-50.